新科学想法 › 学术文库 › 学术文献 › 浏览文献

Aflibercept for the treatment of neovascular age-related macular degeneration

yucloud 添加于 2012-8-9 11:13 | 1207 次阅读 | 0 个评论

作者
Verner-Cole EA, Davis SJ, Lauer AK
摘要
Age-related macular degeneration (AMD) can have devastating effects on vision, especially in its neovascular form. In the last decade, the use of intravitreal pharmacotherapy targeted to vascular endothelial growth factor (VEGF) has significantly improved the visual outcomes in patients with neovascular AMD. Although we have become accustomed to these unprecedented improvement outcomes, maintaining good visual results with anti-VEGF therapy requires tremendous effort, time and cost, typically involving monthly clinic visits and intravitreal injections. The introduction of aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown promise throughout recent clinical trials as an equally effective treatment for neovascular AMD that requires less frequent dosing than either ranibizumab or bevacizumab. Based on clinical trial results, the U.S. Food and Drug Administration approved aflibercept in November 2011 for use in neovascular AMD, giving patients the hope of alleviating some of the burden associated with treatment.
详细资料
- 关键词: Angiogenesis Inhibitors/adverse effects/pharmacokinetics/pharmacology/*therapeutic use; Animals; Choroidal Neovascularization/*drug therapy; Diabetes Complications/drug therapy; Humans; Intravitreal Injections; Macular Degeneration/*drug therapy; Macular Edema/drug therapy; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins/adverse effects/pharmacokinetics/pharmacology/*therapeutic use; Vascular Endothelial Growth Factors/*antagonists & inhibitors
- 文献种类: Journal Article
- 期刊名称: Drugs of Today (Barcelona, Spain : 1998)
- 期刊缩写: Drugs Today (Barc)
- 期卷页: 2012年第48卷第5期 317-329页
- 地址: Oregon Health and Science University, Department of Ophthalmology, Portland, OR, USA
- ISBN: 1699-3993
学科领域生物医药 » 药学
相关链接 DOI URL
yucloud 的文献笔记订阅